Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

203780

Mirae Asset TIGER NASDAQ BIO ETF

The 203780 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: NASDAQ Biotechnology Index. The 203780 ETF provides physical exposure, so by buying it you actually own parts of all the 251 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

₩34,560
+₩80 (+0.23%) today
12:00 AM 07/24/26 Closed
1D price range
₩34,480₩35,160
52W price range
₩22,352.43₩37,545.08
YTD Perf.
+15.92%
YTD Flows
Annualized volatility
Fund AuM
€58M
Share class AuM
€58M
TTM Yield
Tracking Error
Tracking Difference
ISIN
KR7203780002
TER
0.3%
Inception date
8/27/2014
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 30, 2025 - Jul 22, 2026
0%5%10%15%20%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
99.76%
Unavailable
0.22%
Latest 203780 news

No content available for this fund

FAQ about 203780

203780 is a Passive ETF. This ETF provides exposure to US Equities.
203780 tracks the NASDAQ Biotechnology Total Return Index - USD, through a full replication replication method.
203780 carries a total expense ratio (TER) of 0.3%, indicating the annual cost for holding the fund.
203780 was introduced to the market on August 27, 2014. It trades on Tanzania, United Republic of, among other exchanges
Mirae Asset TIGER NASDAQ BIO ETF, 203780, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.
203780 oversees €58M in assets as of July 22, 2026.
203780 follows a distributing dividend policy, meaning it pays out income to investors. As of July 22, 2026, its 12-month trailing yield was 0.46%.
As of June 30, 2026, 203780 has significant geographic allocations in USA, Netherlands and United Kingdom.
As of June 30, 2026, 203780 focuses largely on Healthcare.
As of June 30, 2026, 203780 holds 251 positions in its portfolio, with 49.15% of assets concentrated in its top 15 holdings.
As of June 30, 2026, 203780 top three holdings include Vertex Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc..
The base currency of 203780 is KRW.
Data as of 06/30/26
Vertex Pharmaceuticals, Inc.
8.17%
Amgen, Inc.
7.83%
Gilead Sciences, Inc.
6.88%
Regeneron Pharmaceuticals, Inc.
4.54%
Revolution Medicines, Inc.
2.86%
Alnylam Pharmaceuticals, Inc.
2.73%
Biogen, Inc.
2.23%
Moderna, Inc.
1.93%
Illumina, Inc.
1.91%
Royalty Pharma Plc
1.77%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight